-
Regeneron Is 'One Of The Stronger Growers In Biotech'
Wednesday, June 29, 2016 - 3:04pm | 416Bernstein has initiated coverage of Regeneron Pharmaceuticals Inc (NASDAQ: REGN) with an Outperform rating and $400 price target, citing a "good entry point for one of stronger growers in biotech." "Regeneron is a growth-phase biopharma with one large successful first product (Eylea) and two...